5-fluoro-4-methyl-pyridine-2-carboxylic acid methyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-fluoro-4-methyl-pyridine-2-carboxylic acid methyl ester
• 英文别名: Methyl 5-fluoro-4-methylpicolinate；methyl 5-fluoro-4-methylpyridine-2-carboxylate
• 化学式: C₈H₈FNO₂
• mdl: MFCD18803303
• 分子量: 169.155
• InChiKey: CJWQMQIEJQPIKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-fluoro-4-methyl-pyridine-2-carboxylic acid methyl ester 在 甲醇 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 生成 (5-fluoro-4-methylpyridin-2-yl)methanol
  参考文献：
  名称：

  [EN] MK2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE MK2 ET LEURS UTILISATIONS

  摘要：

  本文介绍了MK2抑制剂和包含该抑制剂的制药组合物。这些化合物和组合物对于治疗自身免疫性疾病、慢性炎症性疾病、急性炎症性疾病、自身炎症性疾病、纤维化性疾病、代谢性疾病、肿瘤性疾病以及心血管或脑血管疾病具有用处。

  公开号：

  WO2022212489A1
• 作为产物：
  描述：

  氰基甲酸甲酯 、 2-fluoro-3-methyl-1-trimethylsilyloxy-1,3-butadiene 以 甲苯 为溶剂， 反应 120.0h， 以36%的产率得到5-fluoro-4-methyl-pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  A novel and versatile access to fluorinated carbo- and heterocyclic compounds employing electron-rich fluorodienes as cycloaddition components

  摘要：

  The readily accessible 2-fluoro-1-trimethylsilyloxy-1,3-dienes undergo Diels-Alder type cycloaddition with a variety of dienophiles under mild conditions. In this way, fluoro-2-cyclohexenols, fluoro-2,5-dihydropyranols, fluoro-2,5-dihydro-2-pyridinols, fluoropyridines, fluoro-3,6-dihydro-1,2-oxazines and fluoropyrroles can be efficiently prepared.

  DOI：

  10.1016/s0040-4020(01)90196-6

文献信息

• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130137688A1

  公开（公告）日：2013-05-30

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013079460A1

  公开（公告）日：2013-06-06

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

  这项发明涉及到式(I)化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知能力下降，如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
• SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2788086A1

  公开（公告）日：2014-10-15
• MK2 INHIBITORS AND USES THEREOF
  申请人：Xinthera, Inc.

  公开号：US20220402892A1

  公开（公告）日：2022-12-22

  Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
• US8741892B2
  申请人：——

  公开号：US8741892B2

  公开（公告）日：2014-06-03